BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016;16:204. [PMID: 27184748 DOI: 10.1186/s12879-016-1550-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Malik AA, Farooq S, Jaswal M, Khan H, Nasir K, Fareed U, Shahbaz S, Amanullah F, Safdar N, Khan AJ, Keshavjee S, Becerra MC, Hussain H. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2021;5:350-6. [PMID: 33770510 DOI: 10.1016/S2352-4642(21)00052-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Nwana N, Marks SM, Lan E, Chang AH, Holcombe M, Morris SB. Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness. PLoS One 2019;14:e0213524. [PMID: 30865724 DOI: 10.1371/journal.pone.0213524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
3 Stockbridge EL, Loethen AD, Annan E, Miller TL. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. PLoS One 2020;15:e0243102. [PMID: 33270737 DOI: 10.1371/journal.pone.0243102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev 2018;31:e00021-18. [PMID: 30021818 DOI: 10.1128/CMR.00021-18] [Cited by in Crossref: 132] [Cited by in F6Publishing: 77] [Article Influence: 33.0] [Reference Citation Analysis]
5 Grijota-Camino MD, Montero N, Luque MJ, Díaz-Jurado M, Sabé N, Pérez-Recio S, Couceiro C, Muñoz L, Cruzado JM, Santin M. Tuberculosis prevention in patients undergoing kidney transplantation: A nurse-led program for screening and treatment. Transpl Infect Dis 2021;:e13603. [PMID: 33745229 DOI: 10.1111/tid.13603] [Reference Citation Analysis]
6 Marx FM, Hauer B, Menzies NA, Haas W, Perumal N. Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries - a model-based cost-effectiveness analysis. BMC Public Health 2021;21:2172. [PMID: 34836526 DOI: 10.1186/s12889-021-12142-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lim R, Jarand J, Field SK, Fisher D. Is Universal Screening Necessary? Incidence of Tuberculosis among Tibetan Refugees Arriving in Calgary, Alberta. Can Respir J 2016;2016:8249843. [PMID: 28127230 DOI: 10.1155/2016/8249843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Stockbridge EL, Miller TL, Carlson EK, Ho C. Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data. BMC Public Health 2018;18:662. [PMID: 29843664 DOI: 10.1186/s12889-018-5578-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, Dowdy D. Model-Based Cost-Effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York and Texas. Clin Infect Dis 2020:ciaa857. [PMID: 32584968 DOI: 10.1093/cid/ciaa857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
10 do Valle Leone de Oliveira SM, Ferreira da Silva E, Coimbra Motta-Castro AR, de Oliveira Landgraf de Castro V, Stábile AC, Mello Miranda Paniago A, Trajman A. Tuberculosis infection among cocaine crack users in Brazil. Int J Drug Policy 2018;59:24-7. [PMID: 29966805 DOI: 10.1016/j.drugpo.2018.06.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Stockbridge EL, Miller TL, Carlson EK, Ho C. Tuberculosis Prevention in the Private Sector: Using Claims-Based Methods to Identify and Evaluate Latent Tuberculosis Infection Treatment With Isoniazid Among the Commercially Insured. J Public Health Manag Pract 2018;24:E25-33. [PMID: 29084120 DOI: 10.1097/PHH.0000000000000628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
12 Dobler CC, Fox GJ, Douglas P, Viney KA, Ahmad Khan F, Temesgen Z, Marais BJ. Screening for tuberculosis in migrants and visitors from high-incidence settings: present and future perspectives. Eur Respir J 2018;52:1800591. [PMID: 29794133 DOI: 10.1183/13993003.00591-2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
13 Onwubiko U, Wall K, Sales RM, Holland DP. Using Directly Observed Therapy (DOT) for latent tuberculosis treatment - A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA. PLoS One 2019;14:e0218373. [PMID: 31226132 DOI: 10.1371/journal.pone.0218373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Haley CA. Treatment of Latent Tuberculosis Infection. Microbiol Spectr 2017;5. [PMID: 28409555 DOI: 10.1128/microbiolspec.TNMI7-0039-2016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
15 Spruijt I, Erkens C, Suurmond J, Huisman E, Koenders M, Kouw P, Toumanian S, Cobelens F, van den Hof S. Implementation of latent tuberculosis infection screening and treatment among newly arriving immigrants in the Netherlands: A mixed methods pilot evaluation. PLoS One 2019;14:e0219252. [PMID: 31260502 DOI: 10.1371/journal.pone.0219252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
16 Mateos J, Estévez O, González-Fernández Á, Anibarro L, Pallarés Á, Reljic R, Gallardo JM, Medina I, Carrera M. High-resolution quantitative proteomics applied to the study of the specific protein signature in the sputum and saliva of active tuberculosis patients and their infected and uninfected contacts. J Proteomics 2019;195:41-52. [PMID: 30660769 DOI: 10.1016/j.jprot.2019.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
17 Loutet MG, Burman M, Jayasekera N, Trathen D, Dart S, Kunst H, Zenner D. National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area. Eur Respir J 2018;51:1701226. [PMID: 29326327 DOI: 10.1183/13993003.01226-2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
18 Thanassi W, Behrman AJ, Reves R, Russi M, Swift M, Warkentin J, Miyakawa R, Wegener D, Budnick L, Murray E, Scarpita A, Hurst BJ, Foster-Chang S, Mathew T, Gruden M, Higashi J, Hudson TW 3rd. Tuberculosis Screening, Testing, and Treatment of US Health Care Personnel: ACOEM and NTCA Joint Task Force on Implementation of the 2019 MMWR Recommendations. J Occup Environ Med 2020;62:e355-69. [PMID: 32730040 DOI: 10.1097/JOM.0000000000001904] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Olsson O, Winqvist N, Olsson M, Olsson P, Björkman P. High rate of latent tuberculosis treatment completion in immigrants seeking asylum in Sweden. Infect Dis (Lond) 2018;50:678-86. [PMID: 29620426 DOI: 10.1080/23744235.2018.1459046] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Godoy P, Alsedà M. Vigilancia de los contactos en la tuberculosis: ¿cómo podemos mejorar la estrategia? Enfermedades Infecciosas y Microbiología Clínica 2019;37:493-5. [DOI: 10.1016/j.eimc.2019.04.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Collins JM, Onwubiko U, Holland DP. QuantiFERON-TB Gold Versus Tuberculin Screening and Care Retention Among Persons Experiencing Homelessness: Georgia, 2015-2017. Am J Public Health 2019;109:1028-33. [PMID: 31095412 DOI: 10.2105/AJPH.2019.305069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Kawatsu L, Uchimura K, Ohkado A. Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data. BMC Infect Dis 2021;21:42. [PMID: 33422003 DOI: 10.1186/s12879-020-05712-1] [Reference Citation Analysis]
23 Liu Y, Phares CR, Posey DL, Maloney SA, Cain KP, Weinberg MS, Schmit KM, Marano N, Cetron MS. Tuberculosis among Newly Arrived Immigrants and Refugees in the United States. Ann Am Thorac Soc 2020;17:1401-12. [PMID: 32730094 DOI: 10.1513/AnnalsATS.201908-623OC] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lal A, Al Hammadi A, Rapose A. Latent Tuberculosis Infection: Treatment Initiation and Completion Rates in Persons Seeking Immigration and Health Care Workers. Am J Med 2019;132:1353-5. [PMID: 31153865 DOI: 10.1016/j.amjmed.2019.04.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
25 Milinkovic DA, Birch S, Scott F, Newbold KB, Hopkins J, Saffie M, Essue BM. Low prioritization of latent tuberculosis infection-A systemic barrier to tuberculosis control: A qualitative study in Ontario, Canada. Int J Health Plann Manage 2019;34:384-95. [PMID: 30402949 DOI: 10.1002/hpm.2670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Rustage K, Lobe J, Hayward SE, Kristensen KL, Margineanu I, Stienstra Y, Goletti D, Zenner D, Noori T, Pareek M, Greenaway C, Friedland JS, Nellums LB, Hargreaves S; ESGITM and ESGMYC study groups. Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. Lancet Infect Dis 2021:S1473-3099(21)00052-9. [PMID: 34363771 DOI: 10.1016/S1473-3099(21)00052-9] [Reference Citation Analysis]
27 Shimabuco AY, Medeiros-Ribeiro AC, Miossi R, Bonfiglioli KR, Moraes JCB, Gonçalves CR, Sampaio-Barros PD, Goldenstein-Schainberg C, Souza FHC, Prado LLD, Ugolini-Lopes MR, Yuki EFVN, Bonfa E, Saad CGS. Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. Clinics (Sao Paulo) 2020;75:e1870. [PMID: 33206754 DOI: 10.6061/clinics/2020/e1870] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Sandgren A, Vonk Noordegraaf-Schouten JM, Oordt-Speets AM, van Kessel GB, de Vlas SJ, van der Werf MJ. Identifying components for programmatic latent tuberculosis infection control in the European Union. Euro Surveill 2016;21. [PMID: 27589214 DOI: 10.2807/1560-7917.ES.2016.21.34.30325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
29 Stagg HR, Flook M, Martinecz A, Kielmann K, Abel Zur Wiesch P, Karat AS, Lipman MCI, Sloan DJ, Walker EF, Fielding KL. All nonadherence is equal but is some more equal than others? Tuberculosis in the digital era. ERJ Open Res 2020;6:00315-2020. [PMID: 33263043 DOI: 10.1183/23120541.00315-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Greenaway C, Pareek M, Abou Chakra CN, Walji M, Makarenko I, Alabdulkarim B, Hogan C, McConnell T, Scarfo B, Christensen R, Tran A, Rowbotham N, van der Werf MJ, Noori T, Pottie K, Matteelli A, Zenner D, Morton RL. The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Euro Surveill 2018;23. [PMID: 29637889 DOI: 10.2807/1560-7917.ES.2018.23.14.17-00543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
31 Bedingfield N, Barss L, Oxlade O, Menzies D, Fisher D. Experiences with latent TB cascade of care strengthening for household contacts in Calgary, Canada. Public Health Action 2021;11:126-31. [PMID: 34567988 DOI: 10.5588/pha.20.0082] [Reference Citation Analysis]
32 Godoy P, Alsedà M, Falguera M, Puig T, Bach P, Monrabà M, Manonelles A. A highly transmissible tuberculosis outbreak: the importance of bars. Epidemiol Infect 2017;145:3497-504. [PMID: 29179780 DOI: 10.1017/S0950268817002588] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Swift MD, Molella RG, Vaughn AIS, Breeher LE, Newcomb RD, Abdellatif S, Murad MH. Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel. Clin Infect Dis 2020;71:284-90. [PMID: 31552416 DOI: 10.1093/cid/ciz817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
34 Lambert LA, Katz D, Feng PJ, Djojonegoro BM, Fair E, Jasuja S, Marantz S, Horsburgh CR Jr, Ho C. Impact of Choice of Test for Latent Tuberculosis Infection on Treatment Acceptance and Completion. Microbiol Insights 2018;11:1178636118811311. [PMID: 30505150 DOI: 10.1177/1178636118811311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Rosales-klintz S, Bruchfeld J, Haas W, Heldal E, Houben RM, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-schouten MJ, de Vries G, Zenner D, van der Werf MJ. Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. Eur Respir J 2019;53:1802077. [DOI: 10.1183/13993003.02077-2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
36 Mateos J, Estévez O, González-Fernández Á, Anibarro L, Pallarés Á, Reljic R, Mussá T, Gomes-Maueia C, Nguilichane A, Gallardo JM, Medina I, Carrera M. Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during Mycobacterium tuberculosis infection. Sci Rep 2020;10:3844. [PMID: 32123229 DOI: 10.1038/s41598-020-60753-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
37 Cho KS. Tuberculosis control in the Republic of Korea. Epidemiol Health 2018;40:e2018036. [PMID: 30081621 DOI: 10.4178/epih.e2018036] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
38 Sumner T, Scriba TJ, Penn-Nicholson A, Hatherill M, White RG. Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Sci Rep 2019;9:11126. [PMID: 31366947 DOI: 10.1038/s41598-019-47645-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
39 Manful A, Waller L, Katz B, Cummins J, Warkentin J, Reagon B, Shaw-Kaikai J, Zhu Y, van der Heijden YF. Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study. BMC Infect Dis 2020;20:592. [PMID: 32778060 DOI: 10.1186/s12879-020-05311-0] [Reference Citation Analysis]
40 Villa S, Codecasa LR, Faccini M, Pontello MM, Ferrarese M, Castellotti PF, Senatore S, Lamberti A, Mazzola E, Perno CF, Campisi D, Saporiti M, Raviglione MC. Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. Eur Respir J 2019;54:1900896. [DOI: 10.1183/13993003.00896-2019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]